Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399006 | 0.91 | CTRB1 (0.42) | CTRB1P2RX4P2RX1P2RX3NPC1 | |
| SCHEMBL1398957 | 0.85 | CTRB1 (0.45) | CTRB1P2RX4P2RX1P2RX3NPC1 | |
| SCHEMBL274967 | 0.77 | P2RX4 (0.58) | CTRB1P2RX4P2RX1P2RX3NPC1 | |
| SCHEMBL8526862 | 0.75 | P2RX4 (0.55) | CTRB1P2RX4P2RX1P2RX3NPC1 | |
| SCHEMBL2202906 | 0.73 | DDB1 (0.44) | CTRB1P2RX4NPC1RAB9AHTR2C | |
| SCHEMBL2202910 | 0.73 | DDB1 (0.44) | CTRB1P2RX4NPC1RAB9AHTR2C | |
| SCHEMBL25176242 | 0.72 | DDB1 (0.48) | CTRB1P2RX4P2RX1P2RX3NPC1 | |
| SCHEMBL28604282 | 0.71 | CASP1 (0.42) | CTRB1P2RX4P2RX1P2RX3NPC1 | |
| SCHEMBL28604283 | 0.71 | CASP1 (0.42) | CTRB1P2RX4P2RX1P2RX3NPC1 | |
| SCHEMBL31229229 | 0.70 | DDB1 (0.49) | CTRB1P2RX4P2RX1P2RX3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0925294-B3 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20160096818-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNFALPHA LEVELS | CELGENE CORPORATION | 2016-04-07 | — | — | US | disclosed |
| EP-2859895-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORPORATION (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2305663-B1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORP (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140187584-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and -1-Oxoisoindolines and Method of Reducing TNFalpha Levels | CELGENE CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20130030021-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and 1-Oxoisoindolines and Method of Reducing TNFalpha Levels | CELGENE CORPORATION (US) | 2013-01-31 | — | — | US | disclosed |
| EP-1956017-B1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and method of reducing TNF alpha levels | CELGENE CORP (US) | 2013-01-23 | — | — | EP | disclosed |
| US-8288415-B2 | Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione | CELGENE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-8158653-B2 | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline | CELGENE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2177517-B1 | Amino substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimide for reducing TNF alpha levels | CELGENE CORP (US) | 2011-10-26 | — | — | EP | disclosed |
| US-6476052-B1 | Isoindolines, method of use, and pharmaceutical compositions | CELGENE CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-6395754-B1 | ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS, ANTIPYRETICS | CELGENE CORPORATION, ET AL. | 2002-05-28 | — | — | US | disclosed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | disclosed |
| US-6335349-B1 | AGENTS THAT REDUCE LEVELS OF TUMOR NECROSIS FACTOR; ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS; TREATMENT OF AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6316471-B1 | TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6281230-B1 | TREATING INFLAMMATION, INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE IN A MAMMAL | CELGENE CORPORATION | 2001-08-28 | — | — | US | disclosed |
| EP-0984955-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNF$g(a) LEVELS | Gelgene Corporation (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0925294-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998054170-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNFα LEVELS | CELGENE CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998003502-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096818-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNFALPHA LEVELS | TNF, NFKBIA, TRAF2 | CTRB1 3113/4885P2RX4 2950/4885P2RX1 2807/4885 |
| US-20140187584-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and -1-Oxoisoindolines and Method of Reducing TNFalpha Levels | TNF, NFKBIA, TRAF2 | CTRB1 3113/4885P2RX4 2950/4885P2RX1 2807/4885 |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, OPRK1, OPRD1 | CTRB1 4302/4885P2RX4 238/4885P2RX1 152/4885 |
| US-20130030021-A1 | Substituted 2-(2,6-Dioxopiperidin-3-yl)-phthalimides and 1-Oxoisoindolines and Method of Reducing TNFalpha Levels | TNF, NFKBIA, TRAF2 | CTRB1 3334/4885P2RX4 2747/4885P2RX1 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.